483-63-6
CAS 483-63-6
483-63-6 (CAS 483-63-6) is a pharmaceutical compound with 3 bioactivity targets and 146 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 14501.572857142857 nM | 70 | - |
| - | Potency | 4451.9625 nM | 8 | - |
| - | IC50 | 19976.309999999998 nM | 1 | - |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Hepatic function abnormal | 17 | 38.924 | 10019670 |
| Hepatomegaly | 12 | 38.543 | 10019842 |
| Rash pruritic | 17 | 38.047 | 10037884 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TRPV4 | Inhibition | - | 28612138 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| CROTAMITON | 21766 | SU | MTHSPL |
| crotamiton | 21766 | IN | RXNORM |
| Eurax | 202842 | BN | RXNORM |
| Crotan | 2049599 | BN | RXNORM |
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Dermatitis | crotamiton | LLT | C0011603 |
| Dermatitis | crotamiton | PT | C0011603 |
| Dermatitis | crotamiton | PT | C0011603 |
| Pruritus | crotamiton | LLT | C0033774 |
| Pruritus | crotamiton | PT | C0033774 |
| Rash | crotamiton | LLT | C0015230 |
| Rash | crotamiton | PT | C0015230 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 483-63-6 used for in pharmaceutical contexts?
483-63-6 (CAS 483-63-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 483-63-6?
483-63-6 has 146 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Hepatic function abnormal, Hepatomegaly, Rash pruritic, Thrombocytopenia, Drug ineffective. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 483-63-6 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Crotamiton with EU status "prohibited".
What clinical phase is 483-63-6 in?
No phase 1-4 clinical development badge is rendered for 483-63-6 because the matched compound identifier rows do not contain a max-phase value.